Revvity Inc. (NYSE: RVTY) has been under pressure over the past year. The stock trades near $98/share, reflecting softer revenue trends and cautious sentiment across the life sciences tools sector. Growth has been uneven, margins have come down from prior years, and the company has been working through a tougher demand environment.
Recently, Revvity reported results that showed encouraging signs of stabilization. Management highlighted stronger cost controls, better operational discipline, and progress in refocusing the portfolio on higher margin segments. These improvements helped support profitability even as instrument demand remained mixed. They also indicate that Revvity is working its way toward a more stable operating foundation.
This article looks at where Wall Street analysts believe Revvity could trade by 2027. We pulled together consensus targets and TIKR’s valuation model to outline the stock’s potential path. These figures reflect analyst expectations and are not TIKR’s own predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Modest Upside
Revvity trades near $98/share, and analysts currently see modest upside from here. The latest average price target is $114/share, which implies about 16% upside from current levels.
Key numbers from the analyst grid:
- High estimate: $135/share
- Low estimate: $100/share
- Median target: $115/share
- Ratings: 9 Buys, 3 Outperforms, 6 Holds
Most estimates cluster in the low $110s, suggesting analysts expect steady but measured gains.
For investors, this places Revvity firmly in the modest upside category. The stock could outperform if profitability strengthens or if revenue stabilizes faster than expected, but sentiment today remains balanced.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
Revvity: Growth Outlook and Valuation
The company’s forward outlook appears stable and supported by consistent fundamentals:
- Revenue growth is projected to reach 4% through 2027
- Operating margins are expected to hold near 28%
- Shares trade at about 19x forward earnings
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 19x forward P E suggests Revvity could reach $115/share by 2027
- That implies about 17% total return, or roughly 8% annualized
These inputs point to a business built on steady execution rather than rapid expansion. Revvity does not need high growth for the stock to work, since strong margins and a reasonable valuation already support predictable compounding.
For investors, Revvity looks more like a stable operator than a high growth story, with returns likely driven by consistent performance and disciplined management rather than dramatic acceleration.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
Revvity benefits from a high margin structure and a business model built on recurring revenue. This helps support earnings even when customer spending is choppy. Management has also been sharpening operational discipline and improving efficiency across the business, which supports profitability.
These positive shifts suggest that Revvity is becoming a more focused and predictable operator.
For investors, this supports the idea that earnings can remain steady even if revenue growth stays modest.
Bear Case: Slow Growth and Past Declines
Despite improving fundamentals, Revvity has faced several years of declining revenue and earnings. Customer budgets remain tight across diagnostics and life sciences, and demand has been uneven. Expectations for growth are still modest, which limits the potential for a sharp rerating.
If revenue fails to stabilize or if margins soften again, the modest upside priced into the shares today could fade. For investors, the main risk is that slow growth continues and keeps the stock from moving significantly higher.
Outlook for 2027: What Could Revvity Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 19x forward P E suggests Revvity could trade near $115/share by 2027. That implies about 17% total return and roughly 8% annualized gains.
This outlook reflects a steady recovery supported by stable margins and a balanced valuation. The model does not assume fast growth, which keeps expectations reasonable.
For investors, Revvity appears to be a stable, moderate upside stock. Stronger returns would require a clearer acceleration in revenue or a more robust improvement in demand, but the current setup supports predictable compounding.
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
